David Eichenbaum, MD, FASRS, recalls an early-career case managing bilateral diabetic macular edema with frequent ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

ORLANDO -- The investigational interleukin (IL)-6 inhibitor vamikibart led to visual improvements in uveitic macular edema in ...

A retrospective analysis of a large cohort of patients with diabetic macular edema showed high prevalence of bilateral ...

At AAO 2025, Genentech reported that vamikibart, a first-in-class IL-6–targeted antibody, led to rapid improvements in visual acuity and macular thickness in patients with uveitic macular edema, ...

Otsuka Pharma enters licensing agreement with 4D Molecular Therapeutics for ophthalmic gene therapy drug candidate, 4D-150: Tokyo Monday, November 3, 2025, 11:00 Hrs [IST] Otsuka ...

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...

Detailed price information for Kyowa Hakko Kogyo Co. Ltd (KYKOF) from The Globe and Mail including charting and trades.

DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years ...

Based on data including more than 788 million patient visits from more than 15,000 ophthalmologists, thousands of eyes were ...

Just as Adverum Biotechnologies' cash reserves were running dry, Eli Lilly has swooped in | Just as Adverum’s cash reserves ...

A large propensity-matched retrospective cohort study showed a small but statistically significant 7% increase in new-onset ...